← Russell 3000 cross-section

ENTA ENANTA PHARMACEUTICALS INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-12, not restated
Healthcare

Scale

Market cap
$409m
Revenue TTM
$65m
Net income TTM
$-63m
Free cash flow
$-37m
Composite score
39.1
Sector rank
#2499

Valuation

P / E
EV / EBITDA
EV / sales
3.4
FCF yield
-9.02%
Earnings yield vs 10-yr
-20.17pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-96.9%
EBITDA margin
ROE
-62.6%
ROIC
Revenue growth
0.7%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In April 2023, we entered into a royalty sale agreement with an affiliate of OMERS, a Canadian public employee pension fund, pursuant to which we were paid a $200.0 million cash purchase price in exchange for 54.5% of our future quarterly royalty payments on net sales of MAVYRET/MAVIRET, after June 30, 2023, through June 30, 2032, subject to a cap on aggregate payments to OMERS equal to 1.42 times the purchase price. For accounting purposes, we continue to record 100% of HCV royalties earned under the AbbVie agreement as royalty revenue in our consolidated statements of operations. …ENANTA PHARMACEUTICALS INC, 10-Q, period ended 2026-06-30, filed 2026-08-12

Read the full passage →